|
Gene: ASAP1 |
Gene summary for ASAP1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ASAP1 | Gene ID | 50807 |
Gene name | ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 | |
Gene Alias | AMAP1 | |
Cytomap | 8q24.21-q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A0A0MRE5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
50807 | ASAP1 | CCI_1 | Human | Cervix | CC | 1.43e-12 | 1.18e+00 | 0.528 |
50807 | ASAP1 | CCI_2 | Human | Cervix | CC | 1.50e-16 | 1.70e+00 | 0.5249 |
50807 | ASAP1 | CCI_3 | Human | Cervix | CC | 7.90e-21 | 1.23e+00 | 0.516 |
50807 | ASAP1 | CCII_1 | Human | Cervix | CC | 6.21e-06 | 3.72e-01 | 0.3249 |
50807 | ASAP1 | AEH-subject1 | Human | Endometrium | AEH | 5.01e-18 | 4.73e-01 | -0.3059 |
50807 | ASAP1 | AEH-subject2 | Human | Endometrium | AEH | 5.60e-08 | 3.70e-01 | -0.2525 |
50807 | ASAP1 | AEH-subject3 | Human | Endometrium | AEH | 8.53e-15 | 4.38e-01 | -0.2576 |
50807 | ASAP1 | AEH-subject4 | Human | Endometrium | AEH | 2.12e-13 | 4.83e-01 | -0.2657 |
50807 | ASAP1 | AEH-subject5 | Human | Endometrium | AEH | 3.54e-08 | 3.82e-01 | -0.2953 |
50807 | ASAP1 | EEC-subject1 | Human | Endometrium | EEC | 8.24e-20 | 6.23e-01 | -0.2682 |
50807 | ASAP1 | EEC-subject2 | Human | Endometrium | EEC | 8.02e-12 | 4.57e-01 | -0.2607 |
50807 | ASAP1 | EEC-subject3 | Human | Endometrium | EEC | 2.95e-11 | 2.92e-01 | -0.2525 |
50807 | ASAP1 | EEC-subject4 | Human | Endometrium | EEC | 5.51e-15 | 4.36e-01 | -0.2571 |
50807 | ASAP1 | EEC-subject5 | Human | Endometrium | EEC | 5.78e-03 | 2.23e-01 | -0.249 |
50807 | ASAP1 | GSM5276937 | Human | Endometrium | EEC | 1.48e-03 | 2.96e-01 | -0.0897 |
50807 | ASAP1 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 6.78e-09 | 6.66e-02 | -0.1869 |
50807 | ASAP1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.67e-12 | -3.41e-02 | -0.1875 |
50807 | ASAP1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 5.34e-13 | 4.35e-02 | -0.1883 |
50807 | ASAP1 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.28e-12 | 1.06e-01 | -0.1934 |
50807 | ASAP1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.11e-21 | -4.68e-02 | -0.1917 |
Page: 1 2 3 4 5 6 7 8 9 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
GO:00430877 | Cervix | CC | regulation of GTPase activity | 79/2311 | 348/18723 | 4.21e-08 | 2.60e-06 | 79 |
GO:00163587 | Cervix | CC | dendrite development | 58/2311 | 243/18723 | 4.52e-07 | 1.76e-05 | 58 |
GO:003133410 | Cervix | CC | positive regulation of protein-containing complex assembly | 55/2311 | 237/18723 | 2.25e-06 | 6.73e-05 | 55 |
GO:00609965 | Cervix | CC | dendritic spine development | 28/2311 | 99/18723 | 1.61e-05 | 3.15e-04 | 28 |
GO:00435476 | Cervix | CC | positive regulation of GTPase activity | 53/2311 | 255/18723 | 8.72e-05 | 1.16e-03 | 53 |
GO:00609984 | Cervix | CC | regulation of dendritic spine development | 18/2311 | 61/18723 | 2.84e-04 | 3.07e-03 | 18 |
GO:19021153 | Cervix | CC | regulation of organelle assembly | 40/2311 | 186/18723 | 2.92e-04 | 3.15e-03 | 40 |
GO:19021171 | Cervix | CC | positive regulation of organelle assembly | 19/2311 | 67/18723 | 3.42e-04 | 3.58e-03 | 19 |
GO:00070092 | Cervix | CC | plasma membrane organization | 28/2311 | 142/18723 | 7.85e-03 | 4.14e-02 | 28 |
GO:004325416 | Endometrium | AEH | regulation of protein-containing complex assembly | 83/2100 | 428/18723 | 3.90e-07 | 1.63e-05 | 83 |
GO:003133416 | Endometrium | AEH | positive regulation of protein-containing complex assembly | 52/2100 | 237/18723 | 1.43e-06 | 4.60e-05 | 52 |
GO:00430878 | Endometrium | AEH | regulation of GTPase activity | 66/2100 | 348/18723 | 1.26e-05 | 2.77e-04 | 66 |
GO:00435477 | Endometrium | AEH | positive regulation of GTPase activity | 48/2100 | 255/18723 | 2.18e-04 | 2.67e-03 | 48 |
GO:00163588 | Endometrium | AEH | dendrite development | 46/2100 | 243/18723 | 2.56e-04 | 3.03e-03 | 46 |
GO:004325417 | Endometrium | EEC | regulation of protein-containing complex assembly | 83/2168 | 428/18723 | 1.44e-06 | 4.64e-05 | 83 |
GO:003133417 | Endometrium | EEC | positive regulation of protein-containing complex assembly | 52/2168 | 237/18723 | 3.68e-06 | 9.90e-05 | 52 |
GO:004308712 | Endometrium | EEC | regulation of GTPase activity | 67/2168 | 348/18723 | 1.84e-05 | 3.43e-04 | 67 |
GO:004354712 | Endometrium | EEC | positive regulation of GTPase activity | 50/2168 | 255/18723 | 1.26e-04 | 1.66e-03 | 50 |
GO:001635813 | Endometrium | EEC | dendrite development | 44/2168 | 243/18723 | 1.72e-03 | 1.34e-02 | 44 |
Page: 1 2 3 4 5 6 7 8 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa0466613 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0414420 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa0466614 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
hsa04144110 | Endometrium | AEH | Endocytosis | 56/1197 | 251/8465 | 2.58e-04 | 2.15e-03 | 1.57e-03 | 56 |
hsa0466615 | Endometrium | AEH | Fc gamma R-mediated phagocytosis | 27/1197 | 97/8465 | 3.02e-04 | 2.39e-03 | 1.75e-03 | 27 |
hsa0414424 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0466621 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
hsa0414434 | Endometrium | EEC | Endocytosis | 57/1237 | 251/8465 | 3.34e-04 | 2.82e-03 | 2.10e-03 | 57 |
hsa0466631 | Endometrium | EEC | Fc gamma R-mediated phagocytosis | 27/1237 | 97/8465 | 5.15e-04 | 3.83e-03 | 2.85e-03 | 27 |
hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa0466620 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
hsa04666110 | Esophagus | ESCC | Fc gamma R-mediated phagocytosis | 63/4205 | 97/8465 | 1.63e-03 | 4.89e-03 | 2.50e-03 | 63 |
hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0466610 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ASAP1 | SNV | Missense_Mutation | c.3286N>T | p.Val1096Phe | p.V1096F | Q9ULH1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD | |
ASAP1 | SNV | Missense_Mutation | c.2803N>G | p.Pro935Ala | p.P935A | Q9ULH1 | protein_coding | tolerated(0.13) | benign(0.049) | TCGA-95-7947-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ASAP1 | SNV | Missense_Mutation | c.575G>T | p.Gly192Val | p.G192V | Q9ULH1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
ASAP1 | SNV | Missense_Mutation | novel | c.3227A>T | p.Tyr1076Phe | p.Y1076F | Q9ULH1 | protein_coding | tolerated(0.08) | probably_damaging(0.992) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ASAP1 | SNV | Missense_Mutation | novel | c.607A>G | p.Ile203Val | p.I203V | Q9ULH1 | protein_coding | deleterious(0.04) | probably_damaging(0.952) | TCGA-22-1016-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ASAP1 | SNV | Missense_Mutation | c.359A>C | p.Lys120Thr | p.K120T | Q9ULH1 | protein_coding | tolerated(0.33) | benign(0.027) | TCGA-22-4599-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ASAP1 | SNV | Missense_Mutation | c.1837G>T | p.Asp613Tyr | p.D613Y | Q9ULH1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-33-6737-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | gemcitabine | PD | |
ASAP1 | SNV | Missense_Mutation | c.1175N>C | p.Arg392Thr | p.R392T | Q9ULH1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-37-3783-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ASAP1 | SNV | Missense_Mutation | novel | c.1198N>T | p.Asp400Tyr | p.D400Y | Q9ULH1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-37-4130-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ASAP1 | SNV | Missense_Mutation | c.1555N>G | p.Met519Val | p.M519V | Q9ULH1 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-39-5036-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |